Risk model for overall survival (OS) based on composite patient-reported outcomes (PROs) in aNSCLC patients treated with first-line (1L) cemiplimab-based therapy

Basit Öğe Kaydı
dc.contributor.authorGandara, D. R.
dc.contributor.authorGogishvili, M.
dc.contributor.authorSezer, A.
dc.contributor.authorMakharadze, T.
dc.contributor.authorGumus, M.
dc.contributor.authorYan, E.
dc.contributor.authorHarnett, J.
dc.date.accessioned2025-11-16T19:33:36Z
dc.date.issued2024
dc.departmentİstanbul Medeniyet Üniversitesi
dc.descriptionAnnual Congress of the European-Society-for-Medical-Oncology (ESMO) -- SEP 13-17, 2024 -- Barcelona, SPAIN
dc.description.abstract[Abstract Not Available]
dc.description.sponsorshipRegeneron Pharmaceuticals, Inc.
dc.description.sponsorshipRegeneron Pharmaceuticals, Inc.
dc.description.sponsorshipEuropean Soc Med Oncol
dc.identifier.doi10.1016/j.annonc.2024.08.1948
dc.identifier.endpageS1092
dc.identifier.issn0923-7534
dc.identifier.issn1569-8041
dc.identifier.startpageS1092
dc.identifier.urihttps://doi.org/10.1016/j.annonc.2024.08.1948
dc.identifier.urihttps://hdl.handle.net/20.500.14730/15095
dc.identifier.volume35
dc.identifier.wosWOS:001326612902472
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.language.isoen
dc.publisherElsevier
dc.relation.ispartofAnnals of Oncology
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WOS_20250302
dc.titleRisk model for overall survival (OS) based on composite patient-reported outcomes (PROs) in aNSCLC patients treated with first-line (1L) cemiplimab-based therapy
dc.typeConference Object

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu